Biotech ETFs can help investors capitalize on health care innovation while avoiding the boom-or-bust nature of individual ...
Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...
David Craig’s operating manual for building biotech companies in today’s market is now available in hardcover and as an ...
Parabilis Medicines, NewLimit, Enliven Therapeutics, and Kardigan bagged the biggest biotech funding rounds overall in June 2026.
1mon
‘Buying stuff like it’s going out of fashion’: Biotech M&A on track for best year since pre-Covid
Driven by looming patent cliffs, newly buoyant public markets, and Big Pharma's race to beef up their pipelines, dealmaking in 2026 is off to a strong start.
As Greater Boston’s biotech industry sheds jobs, three unlikely regions are showing promise as up-and-coming hubs.
Discover Prague's biotech hub, now viewed as the primary ‘entry gateway’ into the wider Central and Eastern European ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results